Another Xarelto lawsuit has joined the ongoing litigation over alleged Xarelto bleeding events.

In this Xarelto lawsuit, Plaintiff Edward P. of New Jersey alleges that Xarelto caused life-threatening side effects.

As there is already a massive Xarelto legal action working its way through the courts, Edward P.’s counsel has filed a short form complaint, incorporating the allegations of the larger Xarelto long form that is common to all cases within the larger Xarelto MDL. As such, the short form is sparse on details about Edward P.’s individual complaints.

In a draft of the Long Form Complaint, plaintiffs make accusations that Xarelto is a dangerous drug, and can lead to Xarelto bleeding incidents.

Xarelto is an anticoagulant or blood thinner, a drug designed to help reduce the risk of developing stroke and pulmonary embolism, medical emergencies where a blood clot forms in the body and blocks the blood vessels that feed vital organs.

Patients with deep vein thrombosis and some other clotting issues are at higher risk of developing such conditions, so are often prescribed Xarelto. But Xarelto lawsuits allege that the drug may work too well.

The draft of the long form complaint holds that the earliest clinical trials for Xarelto, the ones used to get the drug’s FDA approval, “were flawed in design and conducted in a negligent manner.” According to the form, despite concerns including “unauthorized unblinding, falsification, and concerns regarding improprieties in randomization,” Xarelto was ultimately approved by the FDA.

The long form also stated that another study, ROCKET AF, which compared Xarelto to older drugs like Warfarin “was the worst managed warfarin [sic] study group in any previously reported clinical trial involving warfarin.”

The Xarelto MDL goes on to allege that thousands of reports of serious bleeding events have been filed with the FDA, including dozens, if not hundreds of deaths once the drug reached the market.

Per the text of the long form draft, in 2012 alone there were 2,081 reports of Serious Adverse Events filed with the FDA, including 151 deaths, compared with 56 deaths reported among Warfarin users.

The long form draft of the Xarelto MDL holds that the companies that made and sold Xarelto “failed to investigate, research, study, and define, fully and adequately, the safety profile of Xarelto,” and that they “failed to provide adequate warnings, about the true safety risks associated with the use of Xarelto.”

On top of this, the architects of the Xarelto lawsuit allege that the makers of Xarelto, Janssen Pharmaceuticals, marketed the drug as not requiring the dose adjustments, twice daily dosing, and blood monitoring required for Warfarin, despite evidence that these practices could protect patients.

The Xarelto lawsuit contends that the makers of the drug spent at least $11 Million on part of their marketing campaign in 2013 alone; the company made billions in Xarelto sales. The Xarelto lawsuit holds that these sales were partly generated by “aggressive marketing efforts” based on “flawed science.”

The Xarelto Lawsuit is In Re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, filed in the U.S. District Court for the Eastern District of Louisiana.